{"schema_version":"secwatch.filing_event.v1","accession":"0001501697-25-000021","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.143307+00:00","generated_at":"2026-05-17T06:21:09.239356+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart","bullets":["Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.","Cash charges of ~$3.3M for severance and termination-related costs; substantially complete in Q3 2025.","COO Mary DiBiase, CCO Mark Baldry, CLO Natasha Thoren terminated; CMO Christophe Arbet-Engels resigns.","John Volpone appointed COO in addition to his role as President; Executive Chairman Adam Craig oversees clinical development.","Restructuring aims to focus resources on completing the 4WARD Phase 3 trial for chronic neutropenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001501697-25-000021","json":"https://secwatch.observer/filing/0001501697-25-000021.json","markdown":"https://secwatch.observer/filing/0001501697-25-000021.md","text":"https://secwatch.observer/filing/0001501697-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/0001501697-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/xfor-20250915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:21:09.239356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"349415a2dcd0ec5c5b5eb52cdd92dbb2090032c8","claim":"X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.3 million for severance and other employee termination-related costs affecting the Company (reduce its workforce by approximately 50%).","evidence_excerpt":"On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‐term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000021/0001501697-25-000021-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.3 million for severance and other employee termination-related costs"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"reduce its workforce by approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}